Semaglutide and Tirzepatide

Semaglutide and Tirzepatide : Recently, a U.S.-based study published in the Obesity journal revealed that popular weight-loss drugs — semaglutide and tirzepatide — result in significantly lower weight loss in real-world settings compared to the outcomes observed in clinical trials.

• About Semaglutide and Tirzepatide : They are polypeptides (small proteins) that mimic natural hormones in the body, especially GLP-1 (Glucagon-Like Peptide-1), which plays a role in appetite and digestion.

o Both drugs are approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults.

o Difference Between the Two: Semaglutide targets only GLP-1 receptors.

ü Tirzepatide targets both GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors, providing an added mechanism for weight and glucose control.

o Common Side Effects: May include nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion, fatigue, injection site reactions, belching, hair loss, and heartburn.